Reviewing Capstone Therapeutics (NASDAQ:CAPS) and DXP Enterprises (NASDAQ:DXPE)

DXP Enterprises (NASDAQ:DXPE) and Capstone Therapeutics (NASDAQ:CAPS) are both industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Risk & Volatility

DXP Enterprises has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -1.35, meaning that its share price is 235% less volatile than the S&P 500.

Earnings and Valuation

This table compares DXP Enterprises and Capstone Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DXP Enterprises	$2.02 billion	1.17	$88.68 million	$6.01	25.31
Capstone Therapeutics	$48.11 million	0.03	-$21.23 million	($100.60)	-0.02

DXP Enterprises has higher revenue and earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than DXP Enterprises, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

74.8% of DXP Enterprises shares are held by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are held by institutional investors. 22.0% of DXP Enterprises shares are held by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares DXP Enterprises and Capstone Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DXP Enterprises	4.45%	18.67%	5.66%
Capstone Therapeutics	-36.51%	-144.43%	-40.48%

Analyst Recommendations

This is a summary of recent ratings for DXP Enterprises and Capstone Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DXP Enterprises	0	2	3	0	2.60
Capstone Therapeutics	1	0	0	0	1.00

DXP Enterprises currently has a consensus target price of $183.00, indicating a potential upside of 20.30%. Given DXP Enterprises’ stronger consensus rating and higher possible upside, research analysts clearly believe DXP Enterprises is more favorable than Capstone Therapeutics.

Summary

DXP Enterprises beats Capstone Therapeutics on 13 of the 14 factors compared between the two stocks.

About DXP Enterprises

DXP Enterprises, Inc. is a distributor of industrial products and provider of related services. It supplies maintenance, repair and operating products, including bearings, power-transmission components, safety equipment and other industrial supplies to customers in a range of industries. The company also provides pump and rotating-equipment services, such as pump repair and packaged pumping systems, as well as supply-chain services that support customers’ procurement and inventory-management needs.

About Capstone Therapeutics

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.